On June 1, drug maker Apotex announced that its Apobiologix division has received approval from Health Canada for its pegfilgrastim biosimilar, Lapelga. Lapelga is the first pegfilgrastim biosimilar to be approved in a highly regulated territory.
On June 1, drug maker Apotex announced that its Apobiologix division has received approval from Health Canada for its pegfilgrastim biosimilar, Lapelga. Lapelga is the first pegfilgrastim biosimilar to be approved in a highly regulated territory.
Klaus Martin, PhD, president of Apobiologix, hailed the approval, saying, “Biosimilars provide an opportunity for the sustainability of global healthcare systems by increasing competition and reducing costs, and very importantly, giving patients increased access to highly effective and often lifesaving biological drugs.”
Approval of the biosimilar was based on data from a phase 2 pharmacokinetic and pharmacodynamic study in healthy volunteers, and from data from the phase 3 APO-Peg-03 trial in patients with breast cancer who were undergoing chemotherapy. The phase 3 study revealed similar safety profiles between the biosimilar and the US-licensed Neulasta. The biosimilar and its reference also had similar immunogenicity, with a low incidence of anti-drug antibodies observed in both the biosimilar and reference arms.
In bringing its pegfilgrastim to the Canadian market, Apobiologix has requested that the biosimilar be listed as the preferred pegfilgrastim product for reimbursement in Canada. The drug maker has submitted its product to The Canadian Agency for Drugs and Technologies in Health, the nation’s independent health technology assessment body, at a 25% discount to the list price of the reference Neulasta, producing a savings of $626.24 (approximately $484 USD) per 6-mg prefilled syringe.
Currently, the reference pegfilgrastim, at its average cost of approximately $12,525 (approximately $9687 USD) for a patient receiving 5 cycles of chemotherapy, is not widely reimbursed. Neulasta is not a benefit provided under drug plans in British Columbia, Saskatchewan, Ontario, Nova Scotia, Prince Edward Island, or Newfoundland and Labrador. Neulasta is available as a restricted benefit—for example, with prior authorization—in Alberta, Yukon, Northwest Territories, the Non-Insured Health Benefits Program, the Department of National Defense, and Veterans Affairs Canada. In Manitoba, reimbursement for pegfilgrastim is assessed on a case-by-case basis.
In the United States, no pegfilgrastim biosimilar has yet been launched, though Mylan and Biocon's Fulphila has been newly approved by the FDA. Other products await regulatory decisions by the FDA; Apotex has submitted a Biologics License Application (BLA) for Lapelga, and Coherus has resubmitted its BLA for CHS-1701 after having received a Complete Response Letter in 2017.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.